Anti-GP119/ GPR119/ GPCR2 monoclonal antibody

Anti-GP119/ GPR119/ GPCR2 antibody for FACS & in-vivo assay

Target products collectionGo to GPR119/GPR119 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-T93788-Ab-1/ GM-Tg-hg-T93788-Ab-2Anti-Human GPR119 monoclonal antibodyHuman
GM-Tg-rg-T93788-Ab-1/ GM-Tg-rg-T93788-Ab-2Anti-Rat GPR119 monoclonal antibodyRat
GM-Tg-mg-T93788-Ab-1/ GM-Tg-mg-T93788-Ab-2Anti-Mouse GPR119 monoclonal antibodyMouse
GM-Tg-cynog-T93788-Ab-1/ GM-Tg-cynog-T93788-Ab-2Anti-Cynomolgus/ Rhesus macaque GPR119 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-T93788-Ab-1/ GM-Tg-felg-T93788-Ab-2Anti-Feline GPR119 monoclonal antibodyFeline
GM-Tg-cang-T93788-Ab-1/ GM-Tg-cang-T93788-Ab-2Anti-Canine GPR119 monoclonal antibodyCanine
GM-Tg-bovg-T93788-Ab-1/ GM-Tg-bovg-T93788-Ab-2Anti-Bovine GPR119 monoclonal antibodyBovine
GM-Tg-equg-T93788-Ab-1/ GM-Tg-equg-T93788-Ab-2Anti-Equine GPR119 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-T93788-Ab-1/ GM-Tg-hg-T93788-Ab-2; GM-Tg-rg-T93788-Ab-1/ GM-Tg-rg-T93788-Ab-2;
GM-Tg-mg-T93788-Ab-1/ GM-Tg-mg-T93788-Ab-2; GM-Tg-cynog-T93788-Ab-1/ GM-Tg-cynog-T93788-Ab-2;
GM-Tg-felg-T93788-Ab-1/ GM-Tg-felg-T93788-Ab-2; GM-Tg-cang-T93788-Ab-1/ GM-Tg-cang-T93788-Ab-2;
GM-Tg-bovg-T93788-Ab-1/ GM-Tg-bovg-T93788-Ab-2; GM-Tg-equg-T93788-Ab-1/ GM-Tg-equg-T93788-Ab-2
Products NameAnti-GPR119 monoclonal antibody
Formatmab
Target NameGPR119
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody, Therapeutics Target antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-GPR119 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation Lyophilized from sterile PBS, PH 7.4
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species GP119/ GPR119/ GPCR2 VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-T93788
    Target NameGPR119
    Gene ID139760,236781,302813,703368,492134,101083248,524232,100054460
    Gene Symbol and SynonymsGPCR2,GPR119
    Uniprot AccessionQ8TDV5,Q7TQN8
    Uniprot Entry NameGP119_HUMAN,GP119_RAT
    Protein Sub-locationTransmembrane Protein
    CategoryTherapeutics Target
    DiseaseN/A
    Gene EnsemblENSG00000147262
    Target ClassificationGPCR

    The target: GPR119, gene name: GPR119, also named as GPCR2. This gene encodes a member of the rhodopsin subfamily of G-protein-coupled receptors that is expressed in the pancreas and gastrointestinal tract. The encoded protein is activated by lipid amides including lysophosphatidylcholine and oleoylethanolamide and may be involved in glucose homeostasis. This protein is a potential drug target in the treatment of type 2 diabetes.[provided by RefSeq, Jan 2010].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.